Pascal and Francis Bibliographic Databases



Selection :

Permanent link

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling

JULKA, P. K1 ; CHACKO, R. T2 ; DHINDSA, N5 ; MILLER, I. D6 ; MA, D7 ; LIN, B7 ; AWASTHY, B8 ; PEROUOU, C. M4 ; NAG, S3 ; PARSHAD, R1 ; NAIR, A2 ; OH, D. S4 ; HU, Z4 ; KOPPIKER, C. B3 ; NAIR, S2 ; DAWAR, R1
[1] Department of Radiotherapy and Oncology, AIIMS, New Delhi 110029, India
[2] Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu 632004, India
[3] Department of Medical Oncology, HCJMRI, Pune, Maharashtra 411001, India
[4] Departments of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[5] Eli Lilly and Company (India) Pvt. Ltd, Gurgaon, Haryana 122001, India
[6] Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
[7] Eli Lilly and Company, Indianapolis, IN 46285, United States
[8] Health Care Global Enterprises, Curie Centre of Oncology, St John's Hospital Campus, Koramangala, Bangalore 560034, India

British journal of cancer. 2008, Vol 98, Num 8, pp 1327-1335, 9 p ; ref : 1 p.1/4

Scientific domain
Medical oncology
Nature Publishing Group, Basingstoke
Publication country
United Kingdom
Document type
Author keyword
breast cancer chemotherapy gemcitabine gene expression microarrays neoadjuvant therapy
Keyword (fr)
Anticancéreux Cancer du sein Cancérologie Chimiothérapie Cisplatine Doxorubicine Essai clinique phase II Expression génique Facteur prédictif Gemcitabine Homme Séquentiel Traitement néoadjuvant Agent alkylant Anthracyclines Antimétabolite Cancer DNA topoisomerase (ATP-hydrolysing) Dérivé de la pyrimidine Enzyme Fluor Composé organique Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases Pathologie de la glande mammaire Pathologie du sein Platine II Complexe Pyrimidine nucléoside Traitement Tumeur maligne
Keyword (en)
Antineoplastic agent Breast cancer Cancerology Chemotherapy Cisplatin Doxorubicin Phase II trial Gene expression Predictive factor Gemcitabine Human Sequential Neoadjuvant treatment Alkylating agent Anthracyclins Antimetabolic Cancer DNA topoisomerase (ATP-hydrolysing) Pyrimidine derivatives Enzyme Fluorine Organic compounds Topoisomerase II inhibitor Enzyme inhibitor Isomerases Mammary gland diseases Breast disease Platinum II Complexes Pyrimidine nucleoside Treatment Malignant tumor
Keyword (es)
Anticanceroso Cáncer del pecho Cancerología Quimioterapia Cisplatino Doxorubicina Ensayo clínico fase II Expresión genética Factor predictivo Gemcitabina Hombre Secuencial Neocoadyuvante tratamiento Agente alquilante Antraciclinas Antimetabólito Cáncer DNA topoisomerase (ATP-hydrolysing) Pirimidina derivado Enzima Fluor Compuesto orgánico Inhibidor topoisomerase II Inhibidor enzima Isomerases Glándula mamaria patología Seno patología Platino II Complejo Pirimidina nucleósido Tratamiento Tumor maligno
002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors

002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors

Gynecology. Andrology. Obstetrics Tumours
INIST identifier

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web